J Biol Chem, Vol. 274, Issue 38, 27315-27322, September 17, 1999
Direct Transport of Newly Synthesized HLA-DR from the
trans-Golgi Network to Major Histocompatibility Complex
Class II Containing Compartments (MIICS) Demonstrated Using a Novel
Tyrosine-sulfated Chimera*
H. W.
Davidson
From the Department of Clinical Biochemistry and Cambridge
Institute for Medical Research, University of Cambridge, Wellcome
Trust/MRC Building, Addenbrookes Hospital, Hills Road,
Cambridge CB2 2XY, United Kingdom
 |
ABSTRACT |
Binding of antigenic peptides to major
histocompatibility complex (MHC) class II glycoproteins occurs in
specialized endocytic compartments of antigen-presenting cells, which
in man are termed MIICs. Newly synthesized MHC class II molecules are
transported from the trans-Golgi network to MIICs, but
previous studies of this important step in antigen processing have
failed to conclusively determine whether most immature MHC class II
complexes are transported directly to the processing compartments or
are first transiently exposed at the cell surface. To attempt to
resolve this question, I constructed a chimeric HLA-DR
chain
containing two optimal tyrosine sulfation motifs. When expressed in a
human B lymphoblastoid cell line lacking functional DR
chains, the
chimera was correctly incorporated into complexes containing endogenous
and invariant chains, transported to the trans-Golgi
network, and efficiently sulfated. Pulse-chase experiments showed that
the sulfated complexes were rapidly transported to processing
compartments with kinetics consistent with direct transport from the
trans-Golgi network. The rate of maturation was not
significantly altered in cells expressing a temperature-sensitive
mutant of dynamin under conditions where the endocytosis of transferrin
was inhibited by 95%, confirming that endocytosis was not required for
delivery to MIICs. Maturation of MHC class II-containing complexes was
inhibited by aluminum fluoride and brefeldin A, indicating the
involvement of heterotrimeric G-proteins and ADP-ribosylation factor in
the transport event(s). The procedure described provides a unique
mechanism to study critical events in antigen processing and presentation.
 |
INTRODUCTION |
Major histocompatibility complex
(MHC)1 class II glycoproteins
are heterodimers that bind antigenic peptides and present them to
CD4+ "helper" T cells (reviewed in Ref. 1). In man,
expression of MHC class II molecules is generally restricted to
"professional" antigen-presenting cells such as dendritic cells, B
lymphocytes, activated macrophages, granulocytes, and T cells, although
expression by other cell types can be induced by
-interferon. In
each case endosomal compartments enriched in MHC class II and referred
to as MIICs (MHC II compartments) can be detected, which are believed to be the sites of peptide loading (2-6). B lymphoblastoid and B
lymphoma cell lines constitutively express high levels of intracellular and cell surface MHC class II. Therefore, the majority of studies of
human MHC class II-related antigen processing has been conducted using
such cells. Although peptide exchange can occur, it is generally accepted that in B cells most antigenic peptides are loaded onto newly
synthesized class II molecules (7) and that correctly formed

-peptide complexes are subsequently long lived (8). Thus to
understand fully the biochemistry of antigen processing and
presentation, it is necessary to determine the nature and number of
compartments through which newly synthesized MHC class II molecules pass.
In most instances the intracellular trafficking of newly synthesized
proteins can be defined by pulse-chase analysis of
[35S]methionine-labeled molecules. However, investigation
of MHC class II trafficking by this technique is severely complicated by the relatively asynchronous movement of MHC class II chains within
the secretory pathway. In the endoplasmic reticulum (ER) newly
synthesized class II
and
chains associate with the invariant chain (Ii) (9), a chaperone that acts both to mask the peptide binding
groove (10, 11), and direct complexes to endosomal compartments (12,
13). Export from the ER requires the formation of a nonameric complex
comprising an Ii trimer and three associated
and
chains.
Assembly occurs via trimeric, pentameric, and heptameric intermediates
and has an overall half-time of approximately 60 min (14). Thus export
of radiolabeled molecules is asynchronous, since some labeled
or
chains associate with heptameric complexes and are exported within
10 min of the chase period, whereas others associate with Ii trimers
and might still be retained in the ER 2 h later.
Nonameric complexes rapidly traverse the Golgi stack but cannot readily
be detected at the cell surface until 1-2 h after they have acquired
terminal oligosaccharide modifications indicative of delivery to the
trans-Golgi network (TGN) (15). It is accepted that the
complexes are retained in MIICs until peptide loading has occurred;
however, there is still dispute as to whether the majority of 
Ii
complexes are transported directly from the TGN to MIICs (16) or
transiently expressed at, and rapidly endocytosed from, the cell
surface (17).
In order to address the precise post-Golgi trafficking of MHC class II
molecules, an alternative strategy is required that restricts labeling
to those molecules that have already been exported from the ER. Protein
tyrosine sulfation is a ubiquitous late Golgi modification in mammalian
cells that satisfies this requirement (reviewed in Ref. 18). In most
cells it is confined to the trans-Golgi/TGN (19), and
sulfate labeling has been used to study the biogenesis and trafficking
of other TGN-derived vesicles (20, 21). A consensus sulfation motif has
been defined (22), and Spiess and colleagues (23) showed that fusion of
a nonapeptide derived from procholecystokinin to the carboxyl terminus
of either a soluble protein or a type II membrane protein allowed
efficient sulfation of the resulting chimeras. None of the MHC class II
chains contain any recognizable sulfation motif, so in order to obtain
labeling I have created a novel chimeric HLA-DR
chain containing two
optimal tyrosine sulfation motifs. I have expressed this chimera in a B
lymphoblastoid cell line lacking functional DR molecules, and I show
that it correctly associates with
and Ii chains, is efficiently sulfated, and rapidly exported from the TGN. To inhibit
clathrin-mediated endocytosis, without perturbing export from the TGN,
I have utilized a temperature-sensitive mutant of dynamin 1 (24-26). I
show that under conditions where clathrin-dependent
endocytosis of transferrin is inhibited by at least 95%, the rate at
which sulfated MHC class II is delivered to protease-containing
compartments is unchanged. This indicates that most newly synthesized
MHC class II molecules transit directly from the TGN to MIICs in this B
cell line.
 |
MATERIALS AND METHODS |
Cells and Reagents--
Tissue culture media and supplements
were obtained from Sigma. HMy2.DRN cells (27) were provided by Dr. P. Travers (University of London, UK) and maintained in RPMI 1640 containing 10% fetal calf serum, 1% minimum Eagle's medium
non-essential amino acids (Life Technologies, Inc.), 2 mM
Glu, 1 mM sodium pyruvate, 50 IU/ml penicillin, and 50 µg/ml streptomycin in a humified 95% air, 5% CO2
atmosphere at 37 °C. Hybridomas L243 (28), DA6.147, and DA6.231 (29)
were obtained from the European Collection of Animal Cell Cultures
(Salisbury, UK) and propogated as described above. Supernatant from
cultures of TAL14.1 (30) was generously provided by Dr. J. Bodmer
(Oxford, UK). Monoclonal antibody Bü45 (31) was obtained from the
Binding Site (Birmingham, UK), LN2 (32) from Sigma, and 12CA5 (33) from
Roche Molecular Biochemicals. Oligonucleotides were supplied by Genosys
(Cambridge, UK) and molecular biology enzymes by New England Biolabs
(Hitchin, UK). Other reagents were obtained from Sigma except where indicated.
Construction of pYY-DR--
Plasmid pCD1 contains cDNA
encoding human preprocathepsin D (34) between the HindIII
and XbaI sites of pBluescript (Stratagene, Cambridge, UK).
Oligonucleotides encoding the secretogranin I tyrosine sulfation site
(sense 5' TCGAGAGGATCCCCTTCGAAGAGGAACCTGAGTATGGCGCCCCCATGGT 3';
antisense 5' CTAGACCATGGGGGCGCCATACTCAGGTTCCTCTTCGAAGGGG ATCCTC 3') were annealed, digested with BamHI, and ligated into
pCD1 that had been digested with BamHI and XbaI.
The product (pCS1) contained the tyrosine sulfation site in frame with
the cathepsin D signal peptide. A second aliquot of the annealed
oligonuclotides was then digested with BstBI and ligated
into pCS1 cut with NarI and XbaI to produce pCS2.
The mature DR
chain was amplified by polymerase chain reaction from
plasmid pE.DR
(gift of Dr. N. Holmes, University of Cambridge) using
Pfu DNA polymerase (Stratagene) and primers designed to
introduce unique ClaI and XbaI sites (sense 5'
CCATCGATGCACCCGGGGAAGAACATGTGATCATCC AGG 3'; antisense 5'
GGAATTCTAGAGAGGCCCCCTGCGTTCTGC 3'). The product was gel-purified,
ligated into the EcoRV site of pBluescript, excised with
ClaI and XbaI, and ligated into pCS2 cut with
NarI and XbaI to produce pCS3. The entire coding
sequence of pCS3 was excised using XhoI and NotI
and ligated into the mammalian expression vector pBJ (gift of Dr. M. Jackson, Scripps Research Institute) that contains the SR
promoter
(35), bovine growth hormone polyadenylation signal, and aminoglycoside
phosphotransferase gene (36), to form pYY-DR
. Plasmid for
transfection was purified using Qiagen columns (Hybaid, Crawley, UK)
according to the manufacturer's instructions.
Transfection of HMy2.DRN--
HMy2.DRN cells (2 × 107) were collected from culture, washed once with
serum-free Iscove's modified Dulbecco's medium, and resuspended in
0.5 ml of the same medium. After transfer to a 0.4-cm electroporation
cuvette (Bio-Rad) and incubation on ice for 10 min, 10 µg of
pYY-DR
was added, and the incubation was continued for an additional
2 min. The cells were then electroporated at 230 V and 960 microfarads
using a Bio-Rad Gene pulser, allowed to recover on ice for 10 min, then
returned to culture. After 24 h the media was supplemented with
G418 (Calbiochem), initially at 0.9 mg/ml, and after an additional
24 h to a final concentration of 1.8 mg/ml. Resistant clones were
isolated by limiting dilution and, after 2 months at 1.8 mg/ml G418,
maintained in media containing 0.9 mg/ml. A single clone expressing the
modified HLA-DR
chain at high levels (YY1) was obtained and used for
all subsequent experiments.
FACS Analysis--
Cells were collected from culture, washed
twice with phosphate-buffered saline containing 5 mg/ml BSA (PBS/BSA),
and resuspended in PBS/BSA containing 5% (v/v) normal rabbit serum
(1 × 107 cells/ml). After incubation at room
temperature for 30 min to block nonspecific binding sites, the cells
were collected by centrifugation, and resuspended in ice-cold PBS/BSA.
Fluorescein isothiocyanate-conjugated mouse anti-(human HLA-DR) (clone
G46-6; Becton Dickinson, Cowley, UK), or an appropriate isotype control
(Sigma), was added, and the cells were incubated on ice with occasional
mixing for 90 min. They were then washed three times with ice-cold
PBS/BSA, once with PBS, and fixed in PBS containing 2%
paraformaldehyde. Fixed cells were analyzed using a Becton Dickinson FACSort.
Radiolabeling and Immunoprecipitation--
Clone YY1 cells
(1.5 × 107) were collected from culture, washed twice
with PBS/BSA, resuspended in sulfate-free basal medium Eagle's
containing 5% dialyzed newborn calf serum at 1.5 × 106 cells/ml, and incubated in a gassed incubator at
37 °C for 2 h. The cells were then collected by centrifugation
at room temperature (4 min at 250 × g), washed once
with sulfate-free medium lacking bicarbonate, and supplemented with 20 mM Na-Hepes, pH 7.4 (Life Technologies, Inc.), and
resuspended in 200 µl of the same medium. After preincubation at
37 °C for 5 min, 50 µl of medium containing 0.25 mCi
Na235SO4 (lyophilized stock;
Amersham Pharmacia Biotech) was added, and the incubation was continued
for an additional 5-10 min with occasional mixing. The cells were then
transferred to ice, diluted to 10 ml with ice-cold PBS/BSA containing
10 mM sodium sulfate, and collected by centrifugation at
4 °C. After a further wash in PBS/BSA-sulfate the cells were
resuspended at 2.5 × 106 cells/ml in RPMI 1640 containing 10% newborn calf serum, 20 mM Hepes, pH 7.4, adjusted to 1 mM sulfate, and chased at 37 °C for times
as indicated. Finally the cells were collected by centrifugation at
4 °C, the medium discarded, and the cells lysed as described previously (37). Radiolabeled class II was recovered with L243 + protein A ("mature"), or DA6.231 + protein G (total), and Ii with a
combination of Bü45 and LN2 + protein G. Bound proteins were
separated by SDS-PAGE using 12.5% gels and analyzed by phosphorimaging using a Fuji Bas2000 system.
N-Glycanase Digestion--
In some experiments eluted proteins
were precipitated with 10 volumes of acetone previously chilled to
80 °C and collected by centrifugation. The precipitates were
resuspended in 25 µl of 0.1 M sodium phosphate, pH 6.5, containing 10 mM EDTA and 0.1% SDS, and heated to
100 °C for 10 min. The solutions were then cooled to room
temperature, CHAPS added to a final concentration of 1% (w/v), and
incubated for 18 h at 37 °C in the presence or absence of 1 unit of N-glycanase (Roche Molecular Biochemicals). An equal
volume of twice concentrated SDS-PAGE sample buffer was then added, and
the samples were analyzed as described above.
Expression of Dynamints--
Plasmid
pTM1-HA-tsDyn (kindly provided by Dr. S. Schmid, La Jolla,
CA) contains human dynamin 1 having an amino-terminal hemaglutinin epitope tag and the mutation G273D (25). Plasmid pMEP4 (Invitrogen) contains the human metallothionein IIA promotor allowing
inducible expression of heterologous proteins in mammalian cells after
treatment with heavy metal ions (38). It also contains elements
conferring resistance to hygromycin B treatment and the ability to
replicate episomally in some cells. The entire coding sequence was
excised with SpeI and SalI and ligated into the
NheI and XhoI sites of pMEP4 to form pDY8. Clone
YY1 cells were transfected with pDY8 as described above and selected in
medium supplemented with G418 (0.9 mg/ml) and 0.6 mg/ml hygromycin B
(Roche Molecular Biochemicals) at 37 °C. A representative clone
(YY1:DY8) was used for subsequent experiments. Mutant dynamin was
induced by culturing clone YY1:DY8 in medium additionally supplemented
with 100 µM ZnCl2 for 18-24 h at 31 °C.
Following induction, high level expression was maintained in the
absence of zinc for at least 8 h at 31 °C.
Western Blotting--
YY1 cells (2 × 106) were
collected from culture, washed once with PBS, and lysed in PBS
containing 1% Triton X-100 and 1 mM phenylmethylsulfonyl
fluoride (107 cells/ml) at 0 °C. Protein in the
clarified lysates was precipitated by the addition of 6 volumes of
acetone previously cooled to
80 °C and incubated on ice for 10 min. After centifugation at 17,000 × g for 15 min,
precipitates were solubilized in SDS-PAGE sample buffer, separated by
electrophoresis, and transferred to nitrocellulose. Immunological
detection was by chemiluminescence (SuperSignal®, Pierce & Warriner,
Chester, UK) and carried out according to the manufacturer's instructions.
Transferrin Endocytosis Assay--
Endocytosis of transferrin
was measured using a modification of the enzyme-linked immunosorbent
assay protocol of Smythe and colleagues (39). Briefly this involved the
use of biotinylated transferrin (Sigma) rather than BSST and two 2-min
washes with 10 mM HCl, 150 mM NaCl, pH 2, to
remove surface ligand (40) prior to solubilization.
 |
RESULTS |
Expression of a Tyrosine-sulfatable HLA-DR
Chain--
In order
to focus upon movement of newly synthesized MHC class II between the
late Golgi and compartments involved in antigen processing and peptide
loading, I constructed a chimeric DR
chain that could be efficiently
labeled with sulfate. Consideration of the crystal structure of HLA-DR1
(41) suggested that a hydrophilic peptide fused to the amino terminus
of the non-polymorphic
chain would be accessible to
post-translational modification but unlikely to interfere with binding
of Ii. Analysis of the kinetic properties of protein tyrosine
sulfotransferases has shown that the apparent Km of
peptide substrates decreases with increasing number of sulfation sites
(42). Accordingly, I constructed a chimera comprising the human
cathepsin D signal peptide and two repeats of a sequence related to the
sulfation site of bovine secretogranin 1, fused to Glu3 of
HLA-DR
. The predicted structure of this chimera, including the
expected amino terminus following signal peptide cleavage and sites of
protein tyrosine sulfation, is indicated in Fig. 1A.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of a sulfatable
HLA-DR chain. A, schematic
representation of the chimeric cDNA indicating the human cathepsin
D signal peptide (shaded), the tyrosine sulfation sites
(arrows), and residues 3-239 of HLA-DR (gray
box). The predicted amino-terminal region of the expressed protein
(Leu-Val-Arg-Ile-Pro-Phe-Glu-Glu-Glu-Pro-Glu-Tyr-Gly-Glu-Glu-Glu-Pro-Glu-Tyr-Gly-Asp-Ala-Pro-Gly)
and transmembrane domain (black box) are indicated.
B, aliquots of parental (lane 1) or YY1 cells
(lane 2) were collected and processed for immunoblotting
with monoclonal DA6.147 as described above. The arrow
indicates specific staining of the chimeric HLA-DR chain.
C, aliquots of parental (open profile) or YY1
cells (filled profile) were collected and processed for FACS
analysis with fluorescein isothiocyanate-conjugated G46-6 as under
"Materials and Methods." The profile of YY1 cells obtained with an
isotype-matched control was identical to that of the parental
cells.
|
|
LICR-LON-HMy2 is a variant of the plasma cell leukemia-derived B
lymphoblastoid cell line ARH-77 (43). HMy2.DRN was generated by two
rounds of
-irradiation each followed by antibody and
complement-mediated selection. The initial round was directed toward
the HLA-A3 locus and isolated a line (HMy2.A3M) lacking an entire MHC
haplotype. The second round was directed toward HLA-DR and identified a
line (HMy2.DRN) in which the remaining DR
gene was mutated to encode a truncated protein that is rapidly degraded prior to export of 
Ii complexes from the ER (27). The cell expresses cell surface immunoglobulin G (44), HLA-DP, and HLA-DQ but no HLA-DR.
Western blot analysis of the HMy2.DRN-derived clone YY1 generated by
transfection with cDNA encoding the chimeric
chain, using the
DR
-specific antibody DA6.147 (29), demonstrated the stable
expression of the chimeric chain (Fig. 1B, lane 2).
Similarly, FACS analysis confirmed that the chimeric chain restored
surface expression of mature HLA-DR molecules (Fig. 1C).
As shown in Fig. 2,
[35S]sulfate was rapidly incorporated into complexes
containing the chimeric
chain. Without a subsequent chase
incubation, radiolabeled proteins were efficiently precipitated with
antibodies toward the lumenal domain of Ii (Fig. 2, lane 1)
but could not be recovered using L243 (lane 2), an antibody whose epitope is masked in HLA-DR molecules which are associated with
intact Ii (45). Most of the radiolabel recovered using anti-Ii
antibodies was present as a smear of apparent molecular mass of 45-80
kDa. This material was sensitive to digestion with chondroitinase A, B,
C, consistent with previous observations that Ii is the protein core
for B cell chondroitin sulfate proteoglycan (46). After a 2-h chase
incubation less than 5% of the radiolabel was associated with intact
Ii (lane 3) but was efficiently recovered with L243
(lane 4). Radiolabel precipitated with L243 was entirely resistant to chondroitinase digestion (data not shown). This suggests that the chondroitin sulfate present in the un-chased precipitates is
exclusively associated with intact Ii chains, consistent with the
conclusion that the Ii chain must be cleaved at a site membrane proximal to the site of proteoglycan addition in order to reveal the
L243 epitope.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 2.
Expression of sulfated MHC class II molecules
in clone YY1. Clone YY1 was radiolabeled with
[35S]sulfate and chased for 0 (lanes 1 and
2) or 2 h (lanes 3 and 4). MHC
class II molecules were precipitated with antibodies toward Ii
(Ii, lanes 1 and 3) or mature HLA-DR
(DR, lanes 2 and 4), respectively. The
positions of the sulfated and chains and chondroitin sulfate
proteoglycan (CSPG) are indicated.
|
|
Characterization of Sulfated HLA-DR--
At early time points the
chimeric
chain migrated with an apparent molecular mass of 42 kDa
(Fig. 2). Subsequently it was converted in a time-dependent
fashion to a 40-kDa form (Fig. 2, lane 4, and Fig.
5A). This chain could be precipitated with monoclonal DA6.147 (which recognizes both
chain-associated, and free,
chains) from denatured eluates previously precipitated with L243 (Fig.
3A, lane 2), confirming that
it was indeed derived from the chimera. Conversion to the faster
migrating form could be prevented by treatment with the
membrane-permeant thiol protease inhibitor E64d, indicating that it was
the result of proteolytic activity. Surprisingly, in addition to the
40-42-kDa band corresponding to the chimeric
chain, efficient
labeling of the DR
chain was also observed in immunoprecipitates of
both immature and mature molecules (Fig. 2, lanes 1 and
4). This was unexpected since none of the tyrosine residues
in this chain are located within the context of an optimal motif, and
only minor labeling was observed in sulfate-labeled human tonsil cells
(47). I decided to investigate this further.

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 3.
Characterization of sulfated MHC class II
molecules. A, sulfate-labeled HLA-DR molecules were
precipitated with L243 from detergent lysates of clone YY1 cells after
a 2-h chase and eluted with non-reducing SDS sample buffer at 100 °C
(lane 1). Eluted molecules were diluted 20-fold in 20 mM Tris·HCl, pH 7.5, containing 150 mM NaCl
and 1% CHAPS and re-precipitated with DA6.147 (lane 2) or
TAL14.1 (lane 3). B, clone YY1 (lane
1) or HMy2.DRN stably expressing wild-type DR (lane
2) were labeled with [35S]sulfate for 10 min. MHC
class II molecules were recovered using anti-class II antibody DA6.231.
C, clone YY1 cells were radiolabeled with
[35S]methionine as described previously (37) (lanes
1-4) or [35S]sulfate as decribed under "Materials
and Methods" (lanes 5 and 6). Cells were chased
for 4 (lanes 1-4) or 1 h (lanes 5 and
6) in an excess of "cold" label, and MHC class II
molecules were collected with L243. Samples were treated with
N-glycanase as described under "Materials and Methods"
either directly (lanes 5 and 6) or after
re-precipitation of the (lanes 1 and 2) or
(lanes 3 and 4) chains, respectively.
Lanes 1, 3, and 5 show the results of mock
incubations, and lanes 2, 4, and 6 show the
effects of N-glycanase digestion. The arrow shows
the position of deglycosylated chains determined in lane
4.
|
|
To confirm that the 30-kDa sulfated species was indeed the DR
chain,
I re-precipitated denatured eluates previously recovered with L243
(Fig. 3A, lane 1) with either DA6.147 or the DR
chain-specific antibody TAL14.1 (30). As predicted, DA6.147 recognized
the 40-kDa band and TAL14.1 the 30-kDa band in the denatured eluates (Fig. 3A, lanes 2 and 3), confirming that both
HLA-DR subunits were efficiently sulfated in clone YY1 cells. In
contrast, neither the
nor the
chains were labeled with sulfate
when HMy2.DRN cells stably expressing a DR
chain lacking the
sulfation motifs were examined under identical conditions to those used
for clone YY1 cells (Fig. 3B). This suggests that efficient
incorporation of sulfate into the
chain requires the optimal motifs
contained in the chimeric
chain.
In addition to tyrosine residues, sulfate can also be incorporated into
N- and O-linked oligosaccharide chains (reviewed
in Ref. 48). Both the
and the
chains contain
N-linked but not O-linked sugars, so to examine whether
protein or carbohydrate residues were sulfated I treated
immunoprecipitates with N-glycanase. To establish the
mobilities of the de-glycosylated chains, I first treated
immunoprecipitates of [35S]methionine-labeled cells with
N-glycanase (Fig. 3C, lanes 1-4). This led to a
decrease in apparent molecular mass of approximately 8-10 kDa for the
chains (lanes 1 and 2) and 2-3 kDa for the
chains (lanes 3 and 4).
N-Glycanase treatment of immunoprecipitates from
sulfate-labeled cells showed no significant decrease in the amount of
label associated with the deglycosylated
chains, indicating that in
this chain the vast majority of label was associated with the
polypeptide backbone (lanes 5 and 6). In
contrast, no sulfate labeling was observed at the position of the
deglycosylated
chain (Fig. 3C, lane 6, arrowhead),
suggesting that this chain was mainly modified by sulfation of
oligosaccharide residues. The sites of sulfation are summarized
diagrammatically in Fig. 8 (TGN).
Maturation of Sulfated HLA-DR Requires Export from the TGN--
In
order to assess the maturation of HLA-DR molecules, I devised a
two-stage immunoprecipitation protocol. Cell lysates were first
precipitated with monoclonal L243 (which does not recognize "immature" complexes containing intact Ii (Fig. 2)). The material thus collected was defined as mature. Subsequently, HLA-DR molecules in
the unbound fraction were collected by monoclonal DA6.231 (defined as
"residual"). After PhosphorImager analysis processing was
calculated as L243/(L243 + DA6.231).
Previous studies have suggested that proteolytic processing of Ii
requires prior delivery to endocytic compartments (9). To determine
whether processing of the sulfated complexes required prior export from
the TGN, I examined the effects of aluminum fluoride and brefeldin A. These reagents have previously been shown to inhibit the formation of
regulated and constitutive transport vesicles from the TGN, suggesting
that heterotrimeric G-proteins and ADP-ribosylation factor(s) are
involved in these events (49-52). As shown in Fig.
4, exposure to these reagents following a
10-min pulse with radiolabel significantly inhibited maturation of
sulfated HLA-DR in the subsequent chase. A minor fraction was resistant to both reagents under these conditions. This probably reflects those
molecules that had already been exported from the TGN during the
labeling period, since a similar degree of processing was observed
after prolonged incubation at 20 °C (Fig. 4, 1st
column), a temperature at which further export is blocked.
Consistent with this hypothesis, nearly 50% maximal L243 binding of
sulfated complexes was obtained when brefeldin A addition was delayed
until 15 min of the chase at 37 °C had been completed (Fig. 4,
5th column). Together these data strongly suggest
that proteolysis of Ii requires prior export of 
Ii complexes from
the TGN and that similar mechanisms govern the formation of vesicles
destined for MIICs as those destined for constitutive or regulated
secretion.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of the maturation of sulfated MHC
class II molecules. Clone YY1 cells were labeled with
[35S]sulfate for 10 min and chased at 20 °C
(1st column) or 37 °C (2nd to
5th columns). The media were supplemented with a
pre-mixed solution containing 30 mM KF + 100 µM AlCl3 (final concentrations) (AlF,
3rd column), 5 µg/ml (final concentration) BFA
(4th column), or BFA was added after the first 15 min of chase (5th column). Data are calculated
for sulfated chains as (L243/(L243 + DA6.231)) × 100, after
subtraction of the experimental blank (defined as the L243 signal from
cells chased at 0 °C). Mean results from at least three separate
determinations are shown.
|
|
Rapid Movement of Newly Sulfated HLA-DR Molecules to MIICs--
I
next examined the time course of the delivery of sulfated 
Ii
complexes to protease-containing compartments. After an initial lag of
5-10 min, incubation at 37 °C led to a rapid
time-dependent increase in the proportion of sulfated
and
chains that could be recovered with L243 (Fig.
5A, odd lanes). Initially the
42-kDa form of the
chain was the sole form detected (lanes
1-4). After a delay of approximately 20 min, label was also
present in the 40-kDa species, which was the major form detected at all
times after the first 40 min (lanes 5-12). At present the
precise amino terminus of the 40-kDa form has not been determined.
However, the decrease in apparent molecular weight implies removal of
at least 13 amino acids, which would include the first sulfated
tyrosine residue. The most likely scenario therefore is that both of
the potential tyrosine residues in the amino-terminal extension of the
42-kDa chimera are sulfated but that only one tyrosine sulfate residue
is present in the 40-kDa form (summarized in Fig. 8). Consistent with
this conclusion, appropriate correction of the quantitated amount of
L243 precipitable radiolabel associated with both
chain species
produced a result that closely followed that obtained by direct
quantitation of the
chain (compare solid squares in Fig.
5, B and C).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Time course of maturation of sulfated MHC
class II. A, clone YY1 cells were radiolabeled and
chased for 0-4 h. Mature molecules were recovered with L243 (odd
lanes) and MHC class II glycoproteins in the L243-unbound fraction
with DA6.231 (even lanes). Eluates were analyzed by SDS-PAGE
and phosphorimaging). The positions of the and chains are
shown. B, radioactivity recovered by L243 present in the
40-kDa species ( ) or the sum of the 42- and 40-kDa species ( ) is
expressed relative to the total recovered in these forms by both
antibodies. Values relating to the 40-kDa species have been doubled to
account for the loss of tyrosine sulfate during processing.
C, radiolabel recovered by L243 present in the chain is
expressed relative to the sum of that recovered by both antibodies. A
single treatment with L243 maximally recovered 80% of the total
radiolabel collected.
|
|
A recent study using MelJuSo cells concluded that Ii degradation and
peptide loading occurs in distinct intracellular compartments (53).
Thus the appearance of L243-precipitable species of 42 and 40 kDa,
respectively, may reflect delivery to sequential processing compartments (Fig. 8). Consistent with this hypothesis, virtually all
of the BFA-resistant signal observed in the experiments shown in Fig. 4
(5th column) was present as the 42-kDa form (data
not shown).
Cleavage of the carboxyl-terminal region of Ii was essentially complete
after a 2-h chase (Fig. 5). At this time 20-30% of the radiolabel was
present in complexes that were resistant to dissociation by incubation
in SDS sample buffer at room temperature (data not shown). This is
indicative of conformational changes that occur following antigenic
peptide loading of MHC class II molecules (54). Sulfated molecules
could also be detected by cell surface immunoprecipitation using L243
at this time. Together these data suggest that the sulfated
amino-terminal extension does not significantly alter the normal
trafficking or maturation of MHC class II molecules.
Sulfated 
Ii Complexes Are Transported Directly to Proteolytic
Compartments--
At present there is still some debate as to the
precise post-Golgi trafficking routes followed by newly synthesized MHC
class II glycoproteins (for example see Refs. 16, 17, 24, and 55). The
rapid delivery to protease-containing compartments observed in the
present study suggested that in this case trafficking from the TGN to
MIICs was largely independent of prior delivery to the cell surface.
Consistent with this conclusion no significant population of immature
molecules could be detected at the cell surface using antibodies
directed to the lumenal domain of Ii or following biotinylation with
membrane-impermeant reagents (data not shown). However, these
experiments could not eliminate the possibility that the half-time of
immature complexes at the cell surface was too short to allow their
detection. To address this point directly I examined the effect of
expressing a temperature-sensitive mutant of dynamin 1.
Unlike other methods of blocking receptor-mediated endocytosis, the
mutant dynamin does not alter export from the TGN (26). To minimize the
time during which endocytosis was inhibited, I utilized a
temperature-sensitive mutant that is functional at temperatures below
32 °C but acts as a dominant inhibitor at 38 °C (25). Although
mutant protein synthesized at 37 °C does not fold properly and so is
essentially inert (25), my attempts to isolate cells constitutively
expressing high levels of the mutant were unsuccessful, either at 31 or
37 °C. To overcome this I utilized the pMEP4 vector that contains
the human metallothionein IIA promotor and in Epstein-Barr virus
transformed cells replicate episomally. As shown in Fig.
6A, a stable clone capable of
showing a 10-20-fold induction of the mutant protein at the permissive temperature was isolated. The basal expression of the mutant protein at
37 °C was approximately twice that of the endogenous dynamin II
(data not shown) and did not grossly interfere with cell growth.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition by mutant dynamin of transferrin
endocytosis. A, YY1 cells (lane 1),
un-induced YY1:DY8 cells (lane 2), or induced YY1:DY8 cells
(lane 3) were processed for immunoblotting using antibody
12CA5 as described under "Materials and Methods." The
arrow indicates the epitope-tagged mutant dynamin.
B, un-induced ( ) or induced ( ) YY1:DY8 cells were
collected from culture at 31 °C and incubated for 10 min at
38 °C. The cells were precipitated and resuspended in buffer
containing biotinylated transferrin (5 µg/ml). After binding and
washing at 4 °C, the cells were resuspended in media and chased at
38 °C for times as indicated and then processed for enzyme-linked
immunosorbent assay as described under "Materials and
Methods."
|
|
To confirm that the induced mutant protein was functional, I examined
the endocytosis of transferrin. As previously shown for HeLa cells
(25), endocytosis was identical in uninduced and induced cells assayed
at 30 °C. In contrast, uptake in the induced cells was rapidly
inhibited (t1/2 of 2-3 min) upon shift to the
restrictive temperature (data not shown). As shown in Fig.
6B, YY1:DY8 cells induced at the permissive temperature,
shifted to 38 °C for 10 min to achieve the mutant conformation, and
then cooled to 0 °C prior to transferrin binding, showed a 95%
reduction in the rate of endocytosis upon return to 38 °C
(open squares) as compared with uninduced controls
(closed squares).
In contrast, induction of the dynamin-dependent block in
endocytosis in YY1:DY8 cells did not cause cell surface accumulation of
immature 
Ii complexes (data not shown). Similarly, no effect on
the rate of proteolytic maturation of sulfated MHC class II was
observed when compared with mock-treated YY1 cells (Fig.
7). In both cases the rate and extent of
processing was somewhat reduced as compared with untreated controls.
However this appeared to reflect a direct effect of the zinc ions on
the processing enzymes, rather than any inhibition of the membrane
transport pathways.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of mutant dynamin on sulfated MHC
class II processing. Mock-induced YY1 cells ( ) or induced
YY1:DY8 cells ( ) were collected from culture at 31 °C and
depleted of endogenous sulfate at the same temperature for 3 h.
The cells were labeled at 38 °C for 10 min, chased at the same
temperature for times as indicated, and then immunoprecipitated with
L243 and DA6.231 as described under "Materials and Methods."
Results are expressed as the percentatage of the total chain-associated radiolabel recovered with L243.
|
|
 |
DISCUSSION |
A central event in the generation of an adaptive immune response
is the binding of peptide fragments of antigen to MHC class II
glycoproteins and their subsequent presentation to CD4+ T
lymphocytes (reviewed in Ref. 1). The critical reactions occur in
multiple endocytic compartments variously termed MIICs and CIIVs
(reviewed in Refs. 3 and 56) and predominantly involve newly
synthesized MHC class II molecules (7). However, the precise
trafficking routes followed by newly synthesized 
Ii complexes and
the biochemical machinery governing their movement between the TGN and
MIICs remain unclear. Export of newly synthesized MHC class II from the
ER requires the formation of a nonameric complex comprising three

dimers associated with an Ii trimer (14). This is not complete
for 1-2 h after a 10-min pulse, although labeled
and
chains
which have reached or passed beyond the trans-Golgi can
readily be detected within 30 min (15). This means that reagents that
might potentially be used to examine export of MHC class II from the
TGN cannot easily be tested if they also affect export from the ER.
To overcome this problem I designed a strategy based upon protein
tyrosine sulfation. This modification occurs in late Golgi compartments, allows labeling to high specific activity, and has been
used by others (20, 21) to study post-Golgi trafficking events. A
previous study demonstrated that human MHC class II
and
chains
could be sulfated (47); however, labeling periods of 5-7 h were
required suggesting that the modification was considerably sub-stoichiometric. Consistent with this hypothesis, neither chain contains a recognizable tyrosine sulfation motif (22). Other studies
(23) have shown that a nonapeptide derived from procholecystokinin can
be efficiently sulfated when fused to both soluble and membrane proteins and that a synthetic protein containing 12 repeats of a
heptapeptide from bovine secretogranin I can be sulfated
stoichiometrically (57). Accordingly I elected to create an MHC class
II chimera containing optimal sulfation sites.
A key requirement was that the sulfation motif should be accessible to
modification in the TGN but not interfere with the correct assembly of
(
Ii)3 complexes in the ER. Examination of space-filling models generated from the crystal structures of HLA-DR
molecules associated with either an antigenic peptide or CLIP (the
fragment of Ii that occupies the peptide-binding groove) (41, 58)
revealed that the amino terminus of the
chain was exposed at the
surface of the molecule and projected from the face mainly comprised of
the
chain below, and apparently perpendicular to, the
peptide-binding groove. As sulfation motifs are hydrophilic I concluded
that, if fused to the amino terminus of the
chain, such motifs
would probably be accessible to tyrosine sulfotransferases. Similarly
as only 25 amino acid residues in Ii are located between the
transmembrane domain and CLIP, and they apparently lack any ordered
structure (59), I considered it unlikely that a short hydrophilic
peptide fused to the
chain amino terminus would interfere with the
correct assembly of (
Ii)3 complexes. To increase the
specific activity of the chimera I decided to include multiple copies
of the sulfation motif. However, as a large amino-terminal extension
might adversely effect (
Ii)3 complex assembly, I
focused upon a chimera containing two potential sites, and I utilized a
heterologous signal peptide to facilitate the molecular cloning strategy. The data presented in this study clearly demonstrate that
fusion of a 24-residue peptide to the amino terminus of the HLA-DR
chain does not interfere with the correct trafficking or maturation of
MHC class II molecules. In addition to studies of HLA-DR maturation,
this observation may also be applicable to other studies of antigen
presentation. Efficient presentation can be achieved if the CLIP
sequence in Ii is replaced with an antigenic peptide (60). My data
suggest that an alternative strategy in which the antigenic peptide is
fused to the
chain might also be successful.
After a brief labeling period sulfated MHC class II molecules could all
be recovered using antibodies directed toward the lumenal domain of Ii.
This is consistent with the hypothesis that proteolysis (and consequent
loss of this epitope) does not occur until the newly synthesized
complexes have reached MIICs. At early times the major radiolabeled
species recovered was the chrondroitin sulfate proteoglycan form of Ii.
Overall this is a minor Ii species, but it appears to have an important
role since inhibition of its synthesis depresses antigen presentation
(61). The proteoglycan is mainly located at the cell surface (46) but
is rapidly degraded. This suggests that a population of Ii may be
preferentially directed to the plasma membrane, although this may be
independent of association with MHC class II (62). No evidence for such
a route was provided by the present study, although the possibility
that the sulfated glycosaminoglycan chains were rapidly released at the
cell surface, and therefore did not accumulate, was not explored.
Interestingly, a significant fraction of the sulfated Ii could not be
recovered using antibodies to MHC class II despite repeated
precipitations with reagents showing a variety of specificities. This
suggests that multiple populations of chondroitin sulfate-modified Ii
complexes may exist. This possibility has not been fully explored, but
the YY1 cell line could facilitate such studies.
A surprising observation of this study was the efficient sulfation of
the
chain, despite the absence of any recognizable motif. In
contrast to the previous study of sulfation of endogenous molecules
(47), which concluded that the peptide backbone of the
chain was
modified, most if not all of the sulfate incorporated into the
chain in YY1 cells was added to the N-linked oligosaccharide chains. Sulfation of these residues was entirely dependent upon the
presence of the sulfatable
chain, suggesting that the
amino-terminal extension directly influenced the activity of the
oligosaccharide sulfotransferase concerned. This appears possible since
3 (the site of my extension to this chain) is within 5-10 Å of
19 (the single site of oligosaccharide addition) (41) and might
therefore interact with elements of this chain. In contrast residues
78 and
119, the two sites of N-linked oligosaccharide
addition to the
chain, are exposed at the opposite face to the
amino-terminal extension and are therefore unlikely to be influenced by
its presence. At present the substrate determinants that govern the
activities of oligosaccharide-modifying enzymes are largely unknown. My
results suggest that a cluster of negatively charged residues might
enhance the activity of at least one such enzyme.
Incubation at 37 °C led to the rapid degradation of Ii and
consequent appearance of the L243 epitope. A brief lag was observed prior to the onset of proteolysis, which then occurred with a half-time
of 20-30 min. Such kinetics are similar to those exhibited for
movement between the ER and cis-Golgi (63). This suggests that delivery is directly to the site of proteolysis; the kinetics appear too rapid to involve prior exposure at the cell surface or
movement through multiple endocytic compartments. To examine directly
this conclusion, I investigated the effect of expressing a mutant form
of dynamin 1 previously shown to inhibit receptor-mediated endocytosis
in HeLa cells (25). Ii has previously been shown to be rapidly
internalized in a clathrin-dependent manner (17, 64), and
so I reasoned that a selective block in this process would resolve the
question of post-Golgi targeting. Under conditions in which endocytosis
of transferrin was almost completely abolished, no delay in processing
was observed, demonstrating that the majority of MHC class II was
directly targeted to MIICs in YY1 cells.
In contrast, a concurrent study conducted with transfected HeLa cells
demonstrated that a significant proportion of immature class II was
trapped at the plasma membrane by a mutant dynamin (24). However,
unlike the present study, where the mutant phenotype was not induced
until the commencement of the radiolabeling experiment, Wang and
colleagues (24) induced their mutant dynamin 74 h prior to
analysis. As the mutant phenotype is apparent within 48 h of tetracycline removal in these cells (26), the possibility exists that
prolonged disruption of endocytosis may have indirectly affected multiple trafficking pathways in their study. This might also explain
the discrepancy between their results and those of Lui and co-workers
(55), who used an alternative method of disrupting clathrin-dependent events and concluded that most newly
synthesized class II was directly targeted to the endocytic pathway. In
addition, a major factor to be considered in the interpretation of
these and similar studies is the level of expression of MHC class II in
the various experimental systems used. Both tyrosine- and
di-leucine-based TGN-sorting systems have finite capacities (65), and
so it is likely that expression of high levels of immature 
Ii
complexes may saturate the sorting machinery. Typically the levels of
expression of MHC class II molecules in B lymphoblastoid and B lymphoma
cells are significantly greater than in resting B cells (66), although there is extensive variation between individual cell lines. Thus the
apparent discrepancy between the results of previous studies (for
example Refs. 16 and 17) may simply reflect the relative capacities of
the sorting machineries in the cell lines used. Although it is a B
lymphoblastoid line, the YY1 cells developed in the present study have
a lower level of HLA-DR expression relative to other Epstein-Barr
virus-transformed cell lines (data not shown), presumably due to the
absence of a second HLA-DR
gene. This, together with the
correspondingly reduced levels of HLA-DP and -DQ, might ensure that the
relevant trafficking machinery in YY1 cells is not saturated and so
explain the high efficiency of direct targeting observed. Under
physiological conditions most, if not all, B cell antigens are
delivered to MIICs by membrane immunoglobulin. It appears biologically
consistent that nascent MHC class II molecules should also be directly
delivered to these compartments, rather than exposed at the cell
surface where they might be aberrantly processed and hence acquire
inappropriate peptides. This might not be the case for other
antigen-presenting cells having different roles in the immune response.
In summary, the data obtained in the present study indicate that under
conditions where the TGN-based sorting machinery is not saturated most
newly synthesized MHC class II glycoproteins are directly transported
to a processing compartment in which initial cleavage of Ii occurs
(Fig. 8). Subsequently the partially processed complexes are either delivered to a more distal processing compartment or the MIIC in which they reside itself matures in a
BFA-sensitive manner, allowing complete processing of the invariant chain and peptide loading to occur (53). Finally, the mature complexes
are transported to the cell surface by an as yet poorly understood
mechanism.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 8.
Summary of the trafficking of sulfated MHC
class II. Within the TGN, sulfate residues (filled
circles) are added to the protein core of the chain
(open rectangle) and the N-linked oligosaccharide
associated with the chain (hatched rectangle). The
sulfated molecules are directly transported to an "early" MIIC in
which initial cleavage of Ii (filled shape) occurs, exposing
the L243 epitope. Subsequently, the partially processed complex is
exposed to a more proteolytically active environment in which the
remainder of Ii is degraded, and the most amino-terminal sulfate
residue is removed. Both steps are sensitive to BFA.
|
|
 |
ACKNOWLEDGEMENTS |
I thank Nick Holmes, Mike Jackson, Julia
Bodmer, Sandy Schmid, and Paul Travers for the generous gifts of
reagents and my colleagues Paul Luzio, Scottie Robinson, Rainer Duden,
and Paul Lehner for their encouragement and many helpful comments
during this study.
 |
FOOTNOTES |
*
This study was supported by the Wellcome Trust.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Wellcome Trust Senior Research Fellow in Basic Biomedical
Research. To whom correspondence should be addressed. Tel.: 44 1223 336746; Fax: 44 1223 762323; E-mail: hd162@cam.ac.uk.
 |
ABBREVIATIONS |
The abbreviations used are:
MHC, major
histocompatibility complex;
Ii, invariant chain;
ER, endoplasmic
reticulum;
TGN, trans-Golgi network;
CLIP, Class
II-associated invariant chain peptide;
PAGE, polyacrylamide gel
electrophoresis;
PBS, phosphate-bufferedn saline;
BSA, bovine serum
albumin;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
BFA, brefeldin A;
FACS, fluorescence-activated cell sorter.
 |
REFERENCES |
| 1.
|
Watts, C.
(1997)
Annu. Rev. Immunol.
15,
821-850[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Nijman, H. W.,
Kleijmeer, M. J.,
Ossevoort, M. A.,
Oorschot, V. M. J.,
Vierboom, M. P. M.,
Van de Keur, M.,
Kenemans, P.,
Kast, W. M.,
Geuze, H. J.,
and Melief, C. J. M.
(1995)
J. Exp. Med.
182,
163-174[Abstract/Free Full Text]
|
| 3.
|
Kleijmeer, M. J.,
Raposo, G.,
and Geuze, H. J.
(1996)
Methods Companion Methods Enzymol.
10,
191-207
|
| 4.
|
Kleijmeer, M. J.,
Morkowski, S.,
Griffith, J. M.,
Rudensky, A.,
and Geuze, H. J.
(1997)
J. Cell Biol.
139,
639-649[Abstract/Free Full Text]
|
| 5.
|
Peters, P. J.,
Neefjes, J. J.,
Oorschot, V.,
Ploegh, H. L.,
and Geuze, H. J.
(1991)
Nature
349,
669-676[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
West, M. A.,
Lucocq, J. M.,
and Watts, C.
(1994)
Nature
369,
147-151[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Davidson, H. W.,
Reid, P. A.,
Lanzavecchia, A.,
and Watts, C.
(1991)
Cell
67,
105-116[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Lanzavecchia, A.,
Reid, P. A.,
and Watts, C.
(1992)
Nature
357,
249-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Cresswell, P.
(1996)
Cell
84,
505-507[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Teyton, L.,
O'Sullivan, D.,
Dickson, P. W.,
Lotteau, V.,
Sette, A.,
Fink, P.,
and Peterson, P. A.
(1990)
Nature
348,
39-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Roche, P. A.,
and Cresswell, P.
(1990)
Nature
345,
615-618[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Bakke, O.,
and Dobberstein, B.
(1990)
Cell
63,
707-716[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Lotteau, V.,
Teyton, L.,
Peleraux, A.,
Nilsson, T.,
Karlsson, L.,
Schmid, S. L.,
Quaranta, V.,
and Peterson, P. A.
(1990)
Nature
348,
600-605[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Lamb, C. A.,
and Cresswell, P.
(1992)
J. Immunol.
148,
3478-3482[Abstract]
|
| 15.
|
Machamer, C. E.,
and Cresswell, P.
(1982)
J. Immunol.
129,
2564-2569[Abstract]
|
| 16.
|
Bénaroch, P.,
Yilla, M.,
Raposo, G.,
Ito, K.,
Miwa, K.,
Geuze, H. J.,
and Ploegh, H. L.
(1995)
EMBO J.
14,
37-49[Medline]
[Order article via Infotrieve]
|
| 17.
|
Roche, P. A.,
Teletski, C. L.,
Stang, E.,
Bakke, O.,
and Long, E. O.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8581-8585[Abstract/Free Full Text]
|
| 18.
|
Huttner, W. B.
(1988)
Annu. Rev. Physiol.
50,
363-376[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Baeuerle, P. A.,
and Huttner, W. B.
(1987)
J. Cell Biol.
105,
2655-2664[Abstract/Free Full Text]
|
| 20.
|
Tooze, S. A.,
and Huttner, W. B.
(1990)
Cell
60,
837-847[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Miller, S. G.,
and Moore, H. P.
(1992)
Methods Enzymol.
219,
234-250[Medline]
[Order article via Infotrieve]
|
| 22.
|
Rosenquist, G. L.,
and Nicholas, H. B.
(1993)
Protein Sci.
2,
215-222[Abstract]
|
| 23.
|
Leitinger, B.,
Brown, J. L.,
and Spiess, M.
(1994)
J. Biol. Chem.
269,
8115-8121[Abstract/Free Full Text]
|
| 24.
|
Wang, K.,
Peterson, P. A.,
and Karlsson, L.
(1997)
J. Biol. Chem.
272,
17055-17060[Abstract/Free Full Text]
|
| 25.
|
Damke, H.,
Baba, T.,
Van der Bliek, A. M.,
and Schmid, S. L.
(1995)
J. Cell Biol.
131,
69-80[Abstract/Free Full Text]
|
| 26.
|
Damke, H.,
Baba, T.,
Warnock, D. E.,
and Schmid, S. L.
(1994)
J. Cell Biol.
127,
915-934[Abstract/Free Full Text]
|
| 27.
|
Koppelman, B.,
and Cresswell, P.
(1990)
J. Immunol.
145,
2730-2736[Abstract]
|
| 28.
|
Lampson, L. A.,
and Levy, R.
(1980)
J. Immunol.
125,
293-299[Abstract]
|
| 29.
|
Guy, K.,
Van Heyningen, V.,
Cohen, B. B.,
Deane, D. L.,
and Steel, C. M.
(1982)
Eur. J. Immunol.
12,
942-948[Medline]
[Order article via Infotrieve]
|
| 30.
|
Maddox, J. F.,
and Bodmer, J. G.
(1989)
in
Immunobiology of HLA, Immunogenetics and Histocompatibility
(Dupont, B., ed), Vol. II
, pp. 373-375, Springer-Verlag, Berlin
|
| 31.
|
Wraight, C. J.,
van Endert, P.,
Moller, P.,
Lipp, J.,
Ling, N. R.,
MacLennan, I. C. M.,
Koch, N.,
and Moldenhauer, G.
(1990)
J. Biol. Chem.
265,
5787-5792[Abstract/Free Full Text]
|
| 32.
|
Epstein, A. L.,
Marder, R. J.,
Winter, J. N.,
and Fox, R. I.
(1984)
J. Immunol.
133,
1028-1036[Abstract]
|
| 33.
|
Niman, H. L.,
Houghten, R. A.,
Walker, L. E.,
Reisfeld, R. A.,
Wilson, I. A.,
Hogle, J. M.,
and Lerner, R. A.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
4949-4953[Abstract/Free Full Text]
|
| 34.
|
Faust, P. L.,
Kornfeld, S.,
and Chirgwin, J. M.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
4910-4914[Abstract/Free Full Text]
|
| 35.
|
Takebe, Y.,
Seiki, M.,
Fujisawa, J. I.,
Hoy, P.,
Yokota, K.,
Arai, K. I.,
Yoshida, M.,
and Arai, N.
(1988)
Mol. Cell. Biol.
8,
466-472[Abstract/Free Full Text]
|
| 36.
|
Southern, P. J.,
and Berg, P.
(1982)
J. Mol. Appl. Genet.
1,
327-341[Medline]
[Order article via Infotrieve]
|
| 37.
|
Davidson, H. W.
(1995)
J. Cell Biol.
130,
797-805[Abstract/Free Full Text]
|
| 38.
|
McNeall, J.,
Sanchez, A.,
Gray, P. P.,
Chesterman, C. N.,
and Sleigh, M. J.
(1989)
Gene (Amst.)
76,
81-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Smythe, E.,
Redelmeier, T. E.,
and Schmid, S. L.
(1992)
Methods Enzymol.
219,
223-234[Medline]
[Order article via Infotrieve]
|
| 40.
|
Subtil, A.,
Hemar, A.,
and Dautry-Varsat, A.
(1994)
J. Cell Sci.
107,
3461-3468[Abstract]
|
| 41.
|
Brown, J. H.,
Jardetzky, T. S.,
Gorga, J. C.,
Stern, L. J.,
Urban, R. G.,
Strominger, J. L.,
and Wiley, D. C.
(1993)
Nature
364,
33-39[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Niehrs, C.,
Kraft, M.,
Lee, R. W. H.,
and Huttner, W. B.
(1990)
J. Biol. Chem.
265,
8525-8532[Abstract/Free Full Text]
|
| 43.
|
Edwards, P. A |